Polyphor's second PEMdrug candidate (POL7080) is a specific Pseudomonas antibiotic with a novel mode of action. POL7080 is the first of a new class of antibiotic drug candidates derived from the PEMfinder® platform. Preclinical studies have demonstrated the compound to be highly active on a broad panel of clinical isolates including multi-drug resistant Pseudomonas bacteria with outstanding in vivo efficacy in septicemia, lung and thigh infection models. A Phase I clinical trial in healthy volunteers in Europe was successfully completed demonstrating the clinical safety and tolerability of POL7080. All primary study objectives were achieved in this Phase I trial. POL7080 and the follow-on research program are available for partnering.
Licensing opportunities of POL7080 include all indications (sepsis, UTI, VAP, CF, combination therapies, etc.).